{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:30:05Z","timestamp":1726101005434},"reference-count":7,"publisher":"Baishideng Publishing Group Inc.","issue":"31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Clin Cases"],"abstract":"<jats:p>In this editorial we comment on an article published in World Journal of Clinical Cases  in 2024, in which a case of refractory ulcerative colitis (UC) was discussed based on the response to different lines of biologics. Different studies showed that different classes of biologics have their advantages and disadvantages in the treatment of refractory UC. Certain classes are superior to others and if tried earlier on would lead to a possible change in the outcome.<\/jats:p>","DOI":"10.12998\/wjcc.v12.i31.6425","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:52:22Z","timestamp":1726015942000},"page":"6425-6427","source":"Crossref","is-referenced-by-count":0,"title":["Refractory ulcerative colitis: Upadacitinib versus other biologics"],"prefix":"10.12998","volume":"12","author":[{"given":"Said G","family":"Farhat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessy G","family":"Fadel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i29.8776"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac190.0788"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v12.i9.1685"},{"key":"B4","doi-asserted-by":"crossref","unstructured":"Dalal RS, Kallumkal G, Cabral HJ. Comparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis at 8-16 Weeks: A Multicenter Retrospective Cohort Study. Gastroenterol Hepatol (NY) 2023; 19: 3-4","DOI":"10.14309\/01.ajg.0000953040.51406.65"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.08.027"},{"key":"B6","doi-asserted-by":"crossref","unstructured":"Singh A, Khan F, Lopez R, Shen B. Ustekinumab versus Vedolizumab for Moderate to Severe Crohn's Disease. Am J Gastroenterol 2017; 112: S393-S394","DOI":"10.14309\/00000434-201710001-00713"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.12.214"}],"container-title":["World Journal of Clinical Cases"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v12\/i31\/6425.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v12\/i31\/6425.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T03:24:15Z","timestamp":1726025055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v12\/i31\/6425.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":7,"journal-issue":{"issue":"31"},"URL":"https:\/\/doi.org\/10.12998\/wjcc.v12.i31.6425","relation":{},"ISSN":["2307-8960"],"issn-type":[{"value":"2307-8960","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,6]]}}}